Cargando…

Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer

PURPOSE: Genetic alterations such as activating KRAS and/or inactivating TP53 are thought to be the most common drivers to tumorigenesis. Therefore, we assessed phase I cancer patients with KRAS+/TP53+ mutations. RESULTS: Approximately 8% of patients referred to phase I clinical trials harbored conc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Zhijie, Piha-Paul, Sarina, Janku, Filip, Subbiah, Vivek, Shi, Naiyi, Gong, Jing, Wathoo, Chetna, Shaw, Kenna, Hess, Kenneth, Broaddus, Russell, Naing, Aung, Hong, David, Tsimberidou, Apostolia M., Karp, Daniel, Yao, James, Meric-Bernstam, Funda, Fu, Siqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464912/ https://www.ncbi.nlm.nih.gov/pubmed/28430579 http://dx.doi.org/10.18632/oncotarget.16840

Ejemplares similares

Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies
por: Wang, Yudong, et al.
Publicado: (2020)

Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer
por: Wang, Yudong, et al.
Publicado: (2018)

Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic
por: Dembla, Vikas, et al.
Publicado: (2018)

Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences
por: Yao, Shuyang, et al.
Publicado: (2022)

Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience
por: Fu, Siqing, et al.
Publicado: (2015)

Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience
por: Wang, Zhijie, et al.
Publicado: (2016)

Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials
por: Sen, Shiraj, et al.
Publicado: (2018)

Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial
por: Subbiah, Vivek, et al.
Publicado: (2020)

Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience
por: Hou, Ming-Mo, et al.
Publicado: (2016)

Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
por: Reilley, Matthew J., et al.
Publicado: (2017)

BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study
por: Nelson, Blessie Elizabeth, et al.
Publicado: (2023)

Phase 1 trial of ADI‐PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors
por: Yao, Shuyang, et al.
Publicado: (2021)

Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors
por: Thein, Kyaw Z., et al.
Publicado: (2021)

FBXW7 Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors
por: Jardim, Denis L., et al.
Publicado: (2014)

Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience
por: Goldstein, Jennifer B., et al.
Publicado: (2017)

Selinexor in Combination with Carboplatin and Pemetrexed in Patients with Advanced or Metastatic Solid Tumors: Results of an Open-Label, Single-Center, Multi-Arm Phase 1b Study
por: Thein, Kyaw Z., et al.
Publicado: (2022)

Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies
por: Subbiah, Vivek, et al.
Publicado: (2016)

Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials
por: Groisberg, Roman, et al.
Publicado: (2017)

Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi‐arm phase Ib study
por: Thein, Kyaw Zin, et al.
Publicado: (2021)

Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study
por: Thein, Kyaw Zin, et al.
Publicado: (2021)

Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib study
por: Thein, Kyaw Z., et al.
Publicado: (2021)

Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study
por: Thein, Kyaw Z., et al.
Publicado: (2021)

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy
por: Park, Haeseong, et al.
Publicado: (2016)

Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine
por: Tsimberidou, Apostolia-Maria, et al.
Publicado: (2019)

Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials
por: Subbiah, Ishwaria M., et al.
Publicado: (2015)

Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers
por: Sen, Shiraj, et al.
Publicado: (2018)

Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial
por: Mendoza, Tito R., et al.
Publicado: (2022)

Clinical next generation sequencing to identify actionable aberrations in a phase I program
por: Boland, Genevieve M., et al.
Publicado: (2015)

A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies
por: Piha-Paul, Sarina A, et al.
Publicado: (2021)

Associations between the gut microbiome and fatigue in cancer patients
por: Hajjar, Joud, et al.
Publicado: (2021)

Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology
por: Vo, Henry Hiep, et al.
Publicado: (2022)

Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase 1 trials
por: Subbiah, Ishwaria M., et al.
Publicado: (2013)

P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy
por: Said, Rabih, et al.
Publicado: (2013)

Revisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase I Population
por: Wheler, Jennifer, et al.
Publicado: (2013)

Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer
por: Falchook, Gerald S., et al.
Publicado: (2014)

Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies
por: Yao, Shuyang, et al.
Publicado: (2021)

Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer
por: Son, Ji, et al.
Publicado: (2023)

A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation
por: Piha-Paul, Sarina A., et al.
Publicado: (2023)

Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study
por: Tsimberidou, Apostolia Maria, et al.
Publicado: (2021)

Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus
por: Piha-Paul, Sarina A., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1bjfncoadgg9it9ga59etgsj14